Abstract
Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Alzheimer Disease / immunology
-
Amyloid beta-Peptides / immunology
-
Animals
-
Antibodies, Monoclonal / biosynthesis*
-
Antibody Formation*
-
Autoimmune Diseases / drug therapy
-
Biological Products / biosynthesis
-
Biological Warfare / prevention & control
-
Commerce
-
Communicable Diseases, Emerging / immunology
-
Communicable Diseases, Emerging / prevention & control
-
Contraception / methods
-
Glycosylation
-
Humans
-
Immunoglobulin G / therapeutic use
-
Immunoglobulins, Intravenous / therapeutic use
-
Inflammation / drug therapy
-
Mice
-
Nicotiana / immunology
-
Nicotiana / metabolism*
-
Polysaccharides / biosynthesis
-
Pregnancy, Unplanned
-
Respiratory Syncytial Virus Infections / economics
-
Respiratory Syncytial Virus Infections / prevention & control
-
Respiratory Syncytial Viruses / immunology
-
Sexually Transmitted Diseases / prevention & control
-
Vaccines, Subunit / biosynthesis
Substances
-
Amyloid beta-Peptides
-
Antibodies, Monoclonal
-
Biological Products
-
Immunoglobulin G
-
Immunoglobulins, Intravenous
-
Polysaccharides
-
Vaccines, Subunit